Amerigen Pharmaceuticals Inc. is recalling approximately 5,768 bottles of Temozolomide (5 mg) capsules, a prescription chemotherapy medication, because the product failed dissolution specifications. This defect means the capsules may not break down correctly in the body, which could prevent a patient from receiving the full dose of their medication. The recall affects 5-count and 14-count bottles distributed to wholesalers and retailers across the United States. Consumers should contact their healthcare provider or pharmacist immediately to discuss their treatment options.
When a drug fails dissolution specifications, the medication may not be properly absorbed by the body. This can lead to a lower-than-intended dose of the chemotherapy, which may reduce the effectiveness of the treatment for the patient.
Healthcare guidance and product refund
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.